Sweden · Delayed Price · Currency is SEK Magle Chemoswed Holding AB Company Description
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden.
It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease.
The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company’s microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures.
In addition, it is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound care hydrogel for the removal and prevention of wound biofilm; and SmartBone, an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures.
The company was founded in 1944 and is based in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.
| Country | Sweden |
| Founded | 1944 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Justin Pierce |
Contact Details
Address: AgneslundsvAegen 27 Malmö, 212 15 Sweden | |
| Phone | 46 40 38 33 00 |
| Website | maglechemoswed.com |
Stock Details
| Ticker Symbol | MAGLE |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0014401014 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Justin Pierce | Chief Executive Officer |
| Hans Henrik Lidgard | Founder and Chairman |
| Fredrik Andersson | Chief Operations Officer |
| Megi Medzmariashvili | General Counsel |
| Helena Ossmer Thedius | Chief Marketing and Innovation Officer |
| Simon Jegou | Chief Strategy Officer |